Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive ganaxolone versus placebo in female children with PCDH19-related epilepsy
NL-OMON55218Phase 3Completed
- Sponsor
- Marinus Pharmaceuticals
- Start
- May 2020
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ganaxolone in PCDH19 clustering epilepsy (DEE9) (3 arms), sponsored by Marinus Pharmaceuticals. Primary endpoint: Primary efficacy endpoint. Started May 2020; status: completed.
02
Drugs
ganaxolone
03
Conditions
PCDH19 clustering epilepsy (DEE9)
Beyond the preview
Go deeper on NL-OMON55218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55218.